JP2021512917A5 - - Google Patents
Info
- Publication number
- JP2021512917A5 JP2021512917A5 JP2020542801A JP2020542801A JP2021512917A5 JP 2021512917 A5 JP2021512917 A5 JP 2021512917A5 JP 2020542801 A JP2020542801 A JP 2020542801A JP 2020542801 A JP2020542801 A JP 2020542801A JP 2021512917 A5 JP2021512917 A5 JP 2021512917A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- once
- weeks
- composition according
- nemolizumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023155476A JP2023182632A (ja) | 2018-02-09 | 2023-09-21 | 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ |
| JP2025151311A JP2025176134A (ja) | 2018-02-09 | 2025-09-11 | 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628714P | 2018-02-09 | 2018-02-09 | |
| US62/628,714 | 2018-02-09 | ||
| PCT/IB2019/051051 WO2019155427A1 (en) | 2018-02-09 | 2019-02-08 | Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023155476A Division JP2023182632A (ja) | 2018-02-09 | 2023-09-21 | 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ |
| JP2025151311A Division JP2025176134A (ja) | 2018-02-09 | 2025-09-11 | 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512917A JP2021512917A (ja) | 2021-05-20 |
| JP2021512917A5 true JP2021512917A5 (cg-RX-API-DMAC7.html) | 2022-02-15 |
| JP7777921B2 JP7777921B2 (ja) | 2025-12-01 |
Family
ID=65729402
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542801A Active JP7777921B2 (ja) | 2018-02-09 | 2019-02-08 | 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ |
| JP2023155476A Pending JP2023182632A (ja) | 2018-02-09 | 2023-09-21 | 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ |
| JP2025151311A Pending JP2025176134A (ja) | 2018-02-09 | 2025-09-11 | 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023155476A Pending JP2023182632A (ja) | 2018-02-09 | 2023-09-21 | 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ |
| JP2025151311A Pending JP2025176134A (ja) | 2018-02-09 | 2025-09-11 | 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ |
Country Status (23)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202535464A (zh) * | 2023-11-02 | 2025-09-16 | 日商丸寶股份有限公司 | 醫藥組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| DK1188830T3 (da) | 1999-06-02 | 2010-04-26 | Chugai Pharmaceutical Co Ltd | Nyt hæmopoietinreceptorprotein NR10 |
| EP1858924A1 (en) * | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| JP2010210772A (ja) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| CN105859889B (zh) * | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| FI3284480T3 (fi) * | 2015-04-14 | 2025-09-11 | Chugai Pharmaceutical Co Ltd | IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi |
| WO2017093857A1 (en) * | 2015-11-30 | 2017-06-08 | Anacor Pharmaceuticals, Inc. | Topical pharmaceutical formulations for treating inflammatory-related conditions |
-
2019
- 2019-02-08 PL PL19710488.8T patent/PL3749353T3/pl unknown
- 2019-02-08 HR HRP20251101TT patent/HRP20251101T1/hr unknown
- 2019-02-08 FI FIEP19710488.8T patent/FI3749353T3/fi active
- 2019-02-08 SG SG11202007558YA patent/SG11202007558YA/en unknown
- 2019-02-08 MX MX2020008193A patent/MX2020008193A/es unknown
- 2019-02-08 DK DK19710488.8T patent/DK3749353T3/da active
- 2019-02-08 LT LTEPPCT/IB2019/051051T patent/LT3749353T/lt unknown
- 2019-02-08 EP EP25189672.6A patent/EP4644424A3/en active Pending
- 2019-02-08 RU RU2020129578A patent/RU2758378C1/ru active
- 2019-02-08 PT PT197104888T patent/PT3749353T/pt unknown
- 2019-02-08 JP JP2020542801A patent/JP7777921B2/ja active Active
- 2019-02-08 CA CA3090062A patent/CA3090062A1/en active Pending
- 2019-02-08 AU AU2019219608A patent/AU2019219608B2/en active Active
- 2019-02-08 CN CN201980024489.7A patent/CN112040976A/zh active Pending
- 2019-02-08 SI SI201930960T patent/SI3749353T1/sl unknown
- 2019-02-08 ES ES19710488T patent/ES3049513T3/es active Active
- 2019-02-08 EP EP19710488.8A patent/EP3749353B1/en active Active
- 2019-02-08 WO PCT/IB2019/051051 patent/WO2019155427A1/en not_active Ceased
- 2019-02-08 BR BR112020016144-6A patent/BR112020016144A2/pt unknown
- 2019-02-11 TW TW108104519A patent/TWI856006B/zh active
- 2019-02-11 TW TW113115277A patent/TWI923998B/zh active
-
2020
- 2020-08-05 PH PH12020551185A patent/PH12020551185A1/en unknown
- 2020-08-05 IL IL276524A patent/IL276524A/en unknown
- 2020-08-07 US US16/988,554 patent/US12435147B2/en active Active
- 2020-08-07 CL CL2020002050A patent/CL2020002050A1/es unknown
-
2023
- 2023-09-21 JP JP2023155476A patent/JP2023182632A/ja active Pending
-
2025
- 2025-09-11 JP JP2025151311A patent/JP2025176134A/ja active Pending
- 2025-09-12 US US19/327,709 patent/US20260008859A1/en active Pending
-
2026
- 2026-01-13 AU AU2026200182A patent/AU2026200182A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521797A5 (cg-RX-API-DMAC7.html) | ||
| JP2015512406A5 (cg-RX-API-DMAC7.html) | ||
| SG195049A1 (en) | Methods of treating multiple sclerosis and preserving and/or increasing myelin content | |
| JP2004527551A5 (cg-RX-API-DMAC7.html) | ||
| Storms et al. | Effectiveness of azelastine nasal solution in seasonal allergic rhinitis | |
| JP2018526412A5 (cg-RX-API-DMAC7.html) | ||
| KR20120050473A (ko) | 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도 | |
| IE61120B1 (en) | The use of D-fenfluramine for the manufacture of medicaments for treating depression | |
| JP2017508737A5 (cg-RX-API-DMAC7.html) | ||
| WO2011022633A3 (en) | Method of threating cancer | |
| MX2025012741A (es) | Composiciones farmaceuticas orales | |
| JP2023182632A5 (cg-RX-API-DMAC7.html) | ||
| US10548870B2 (en) | Method for treating multiple sclerosis | |
| JP2009538935A5 (cg-RX-API-DMAC7.html) | ||
| Arshad et al. | Ischemic stroke and post-stroke depression: the role of agomelatine | |
| EP3558378A1 (en) | Low dose drug combinations for use in preventing and treating neuronal damage | |
| WO2022265960A1 (en) | Prevention and treatment of neuronal damage with pyridoindolobenz[b, d] azepine compositions | |
| US6455553B1 (en) | Method for treating a demyelinating condition | |
| CA2469702A1 (en) | Darifenacin for use in the treatment of urgency induced by overactive bladder | |
| CN112437661A (zh) | 苯甲酸或其盐用于预防或治疗抗n-甲基-d-天冬氨酸受体脑炎的用途 | |
| US20260091012A1 (en) | Methods Of Treating Meduloblastoma With Thyroid Hormone | |
| RU2283097C2 (ru) | Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны | |
| RU2824607C2 (ru) | 2-(имидазол-4-ил)-этанамид пентандиовой-1,5 кислоты или его фармацевтически приемлемая соль для лечения covid-19 и ее симптомов | |
| WO2025264860A3 (en) | Methods of treating post-covid airway disease | |
| EA049313B1 (ru) | Применение 2-(имидазол-4-ил)этанамид пентандиовой-1,5 кислоты для лечения covid-19 |